NCT02868580View on ClinicalTrials.gov

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2018

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Triumeq

Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.

Trial Locations (4)

2050

Brain and Mind Centre, Sydney

2109

Macquarie Neurology, North Ryde

2150

Westmead Hospital, Parramatta

3162

Calvary Health Care Bethlehem, Caulfield South

Sponsors
All Listed Sponsors
collaborator

Macquarie University, Australia

OTHER

collaborator

Westmead Hosptial

UNKNOWN

collaborator

Calvary Health Care Bethlehem

UNKNOWN

collaborator

The University of Sydney - Brain and Mind Centre

UNKNOWN

lead

Neuroscience Trials Australia

OTHER

NCT02868580 - Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). | Biotech Hunter | Biotech Hunter